PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
35.66%
Net income growth 1.25-1.5x CRWD's 30.05%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
-4.48%
Negative yoy D&A while CRWD is 6.21%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-150.58%
Negative yoy deferred tax while CRWD stands at 61.99%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
3.40%
Less SBC growth vs. CRWD's 13.23%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
5.93%
Slight usage while CRWD is negative at -200.00%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
-562.34%
Both yoy AR lines negative, with CRWD at -124.34%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-1143.75%
Negative yoy inventory while CRWD is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
300.00%
AP growth well above CRWD's 184.01%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
47.16%
Lower 'other working capital' growth vs. CRWD's 100.00%. David Dodd would see fewer unexpected short-term demands on cash.
-7.95%
Negative yoy while CRWD is 14.15%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
3.24%
Some CFO growth while CRWD is negative at -13.35%. John Neff would note a short-term liquidity lead over the competitor.
-34.69%
Negative yoy CapEx while CRWD is 64.44%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
55.36%
Acquisition growth of 55.36% while CRWD is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
33.90%
Purchases well above CRWD's 31.64%. Michael Burry would see major cash outflow into securities vs. competitor’s approach, risking near-term FCF.
-40.91%
Both yoy lines are negative, with CRWD at -36.63%. Martin Whitman suspects an environment prompting fewer sales or fewer maturities within the niche.
90.46%
We have some outflow growth while CRWD is negative at -9.26%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-19.03%
We reduce yoy invests while CRWD stands at 52.10%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-1496.21%
We cut debt repayment yoy while CRWD is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
23.46%
We slightly raise equity while CRWD is negative at -200.00%. John Neff sees competitor possibly preserving share count or buying back shares.
14.40%
Buyback growth of 14.40% while CRWD is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.